NEW APPROACHES TO HYPONATRAEMIA: THE VAPTANS

The vaptans represent a new class of drug indicated for the treatment of hyponatraemia due to heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The review critically considers the evidence basis, which supports the use of the vaptans in clinical practice. Keywords: Hyponatraemia, Tolvaptan, Conivaptan, SIADH, Heart Failure